Fresenius Medical Care AG American Depositary Shares (Each representing (FMS) Covered Calls
Fresenius Medical Care AG (FMS) is the world's leading provider of products and services for individuals with renal diseases. Headquartered in Germany, the company operates a global network of dialysis clinics and manufactures a comprehensive range of dialysis equipment, including machines, dialyzers, and related disposables for both clinical and home-based care.
You can sell covered calls on Fresenius Medical Care AG American Depositary Shares (Each representing to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for FMS (prices last updated Fri 4:16 PM ET):
| Fresenius Medical Care AG American Depositary Shares (Each representing (FMS) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 22.77 | +0.03 | 22.32 | 23.79 | 342K | 5.8 | 13 |
| Covered Calls For Fresenius Medical Care AG American Depositary Shares (Each representing (FMS) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 15 | 22.5 | 0.00 | 23.79 | -5.4% | -89.6% | |
| Jun 18 | 22.5 | 0.05 | 23.74 | -5.2% | -33.9% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Core Business and Products
Fresenius Medical Care (FMS) is a vertically integrated healthcare giant specializing in kidney care. Its business is split into two primary segments: Care Delivery (dialysis services) and MedTech (dialysis products). As of 2026, FMS operates over 4,000 dialysis clinics worldwide, serving approximately 350,000 patients. The company is a pioneer in High-Volume Hemodiafiltration (Hv-HDF) and is currently rolling out its 5008X CAREsystem in the U.S. market to improve patient outcomes and clinical efficiency.
In 2026, the company is undergoing a major structural transformation under its "FME25+" program, aiming to simplify its operating model and significantly reduce costs. Despite headwinds from rising labor costs and the potential long-term impact of GLP-1 drugs on the chronic kidney disease (CKD) population, FMS remains the dominant global player. Its product portfolio includes hemodialysis machines, peritoneal dialysis cyclers, and a vast array of consumables like dialyzers and bloodlines.
Competitive Landscape
FMS operates in a highly consolidated market, particularly in the United States. Its primary 2026 rivals include:
DaVita Inc. (DVA): The most significant direct competitor in the U.S. dialysis services market. While FMS is vertically integrated, DaVita focuses primarily on service delivery and clinical innovation.
Baxter International (BAX): A major global competitor in the MedTech segment, particularly strong in home peritoneal dialysis products and advanced organ support therapies.
B. Braun: A German-based competitor that challenges FMS globally in both dialysis equipment manufacturing and the operation of outpatient renal clinics.
Outset Medical (OM): A disruptive player in the MedTech space with its Tablo Hemodialysis System, aiming to simplify dialysis and push more treatments into the home and sub-acute settings.
Strategic Outlook and Innovation
The 2026 outlook for FMS is defined by margin expansion and capital returns. Management has issued guidance for stable revenue growth while prioritizing a €1 billion share buyback program. Innovation is centered on "home-first" initiatives, utilizing digital health platforms to monitor patients remotely. The company is also expanding into value-based care models, which incentivize better patient outcomes over traditional volume models.
For the income-focused investor, FMS is optionable with moderate liquidity. While it has a functional options chain, the volume is lower than that of **DaVita**. For covered call writing, FMS offers a relatively stable underlying price (Beta of ~0.90), making it a candidate for conservative yield-enhancement strategies, though the bid-ask spreads on the ADR can occasionally be wider than those of U.S.-domiciled giants.
| Top 10 Open Interest For May 15 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | TLT covered calls | 1. | POET covered calls | |
| 2. | SLV covered calls | 7. | HYG covered calls | 2. | CMPX covered calls | |
| 3. | IBIT covered calls | 8. | QQQ covered calls | 3. | TEAM covered calls | |
| 4. | GLD covered calls | 9. | KWEB covered calls | 4. | AAOI covered calls | |
| 5. | SPY covered calls | 10. | EEM covered calls | 5. | ENPH covered calls | |
Want more examples? FMNB Covered Calls | FMX Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
